Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review
DOI:
https://doi.org/10.12775/JEHS.2023.23.01.005Keywords
betablocker, blood glucoseAbstract
Introduction: Blood sugar level impairment, especially diabetes mellitus (DM) is a significant problem.
DM leads to many serious complications. Patients suffering from cardiac failure (HF) and diabetes have a risk of hospitalization increased 1.5 times compared to the control group without DM. That is why it is very important to keep appropriate glycemic control. β-blockers, are considered to cause a blood glucose level impairment. The relationship between the use of β-blockers and the development of DM is one of the most interesting and controversial issues in diabetology. Despite many benefits, some doctors are reluctant to prescribe β-blockers because of perceived negative metabolic effects.Aim of study: The purpose of the study was to review the literature describing oral β-blockers, used in HF, influence on glucose metabolism and to discover the best β-blocker treatment for cardiac failured diabetics and prediabetics.
Methods: A systemic review was conducted using PubMed, ScienceDirect, Google Scholar databases. The search strategy was based on the following terms: beta-blocker, blood glucose level, metoprolol, nebivolol, carvedilol, bisoprolol.
Results: β-blockers differ in terms of their mechanism of action and their effects on glucose metabolism. Metoprolol is associated with a worsening of glucose and lipid control. Bisoprolol have a neutral impact on glucose metabolism. Vasodilating β-blockers may improve glycemic profile.Conclusions: All four β-blockers used in HF have similar blood pressure lowering effect but different metabolic effect. Metoprolol should not be used as a drug of choice in patients with impaired glucose metabolism. Bisoprolol, nebivolol or carvedilol may be recommended as a drug of choice in patients with cardiac failure and impaired carbohydrate metabolism. The choice between bisoprolol and vasodilating β-blockers in patients with glycemic disorders is still an unresolved issue.
References
Farzam K, Jan A. Beta Blockers. 2022 Dec 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30422501.
prof. dr hab. n. med. Krzysztof J. Filipiak1, lek. Michał Sokólski2 Leki beta-adrenolityczne — klasyfikacja
i wskazania terapeutyczne 1I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego
Oddział Chorób Wewnętrznych z Pododdziałem Kardiologicznym, z Pododdziałem Wszczepiania Rozruszników Serca i Intensywnego Nadzoru Kardiologicznego NZOZ Szpitala im. prof. S.T. Dąbrowskiego
w Puszczykowie
"Comparison of Oral Beta-Blockers". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Archived from the original on October 18, 2017. Retrieved April 30, 2017.
Dickstein K., Cohen-Solal A., Filippatos G. i wsp.; Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur. Heart J. 2008; 29: 2388–2442.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol
Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13.
Barrese V., Taglialatela M. New advances in beta-blocker therapy in heart failure. Front. Physiol. 2013;4:323. doi: 10.3389/fphys.2013.00323.
Lymperopoulos A., Rengo G., Koch W.J. Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ. Res. 2013;113:739–753. doi: 10.1161/CIRCRESAHA.113.300308.
Packer M., Fowler M.B., Roecker E.B. i wsp. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194–2199.
Hjalmarson A., Goldstein S., Fagerberg B. i wsp. Effects of controlled release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention
Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295–1302.
Dorian P, Angaran P. β-Blockers and atrial fibrillation: hypertension and other medical conditions influencing their use. Can J Cardiol. 2014 May;30(5 Suppl):S38-41. doi: 10.1016/j.cjca.2013.09.029. Epub 2013 Oct 9. PMID: 24530215.
Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010 Mar;26(3):615-29. doi: 10.1185/03007990903533681. PMID: 20067434.
Yilmaz MB, Refiker M, Guray Y, Guray U, Altay H, Demirkan B, Caldir V, Korkmaz S. Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life? Int J Clin Pract. 2007 Feb;61(2):225-30. doi: 10.1111/j.1742-1241.2006.01157.x. PMID: 17263710.
Suskin N, McKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000 Aug;21(16):1368-75. doi: 10.1053/euhj.1999.2043. PMID: 10952826.
MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D,
Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J. 2008 May;29(10):1224-40. doi: 10.1093/eurheartj/ehn156. Epub 2008 Apr 18. PMID: 18424786.
Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005 Sep 20;46(6):1019-26. doi: 10.1016/j.jacc.2005.02.093. PMID: 16168285.
Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 Jun 5;103(22):2668-73. doi: 10.1161/01.cir.103.22.2668. PMID: 11390335.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405. PMID: 10938048; PMCID: PMC27454.
Alhayek S, Preuss CV. Beta 1 Receptors. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30422499.
Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992 Aug;1(2):92-101. doi: 10.3109/08037059209077499. PMID: 1366265.
Large V, Hellström L, Reynisdottir S, Lönnqvist F, Eriksson P, Lannfelt L, Arner P. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest. 1997 Dec 15;100(12):3005-13. doi: 10.1172/JCI119854. PMID: 9399946; PMCID: PMC508512.
Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther. 1992 Jun;17(3):155-64. doi: 10.1111/j.1365-2710.1992.tb01285.x. PMID: 1353501.
Granneman JG. Why do adipocytes make the beta 3 adrenergic receptor? Cell Signal. 1995 Jan;7(1):9-15. doi: 10.1016/0898-6568(94)00066-k. PMID: 7756115.
Wołowiec Ł, Grześk G, Osiak J, Wijata A, Mędlewska M, Gaborek P, Banach J, Wołowiec A, Głowacka M. Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view. Front Pharmacol. 2023 Jan 9;13:1043714. doi: 10.3389/fphar.2022.1043714. PMID: 36699057; PMCID: PMC9868422.
Messerli FH, Grossman E. beta-Blockers in hypertension: is carvedilol different? Am J Cardiol. 2004 May 6;93(9A):7B-12B. doi: 10.1016/j.amjcard.2004.01.020. PMID: 15144930.
Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007 Aug;9(4):269-77. doi: 10.1007/s11906-007-0050-2. PMID: 17686376.
Tang WH. A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus. Vasc Health Risk Manag. 2007;3(5):639-45. PMID: 18078015; PMCID: PMC2291308.
Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006 Jul;99(7):431-6. doi: 10.1093/qjmed/hcl059. Epub 2006 Jun 9. PMID: 16766516.
DeFronzo, R.A., Mandarino, L. and Ferrannini, E. (2003). Metabolic and Molecular Pathogenesis of Type 2 Diabetes Mellitus. In International Textbook of Diabetes Mellitus (eds DeFronzo, Ferraninni, Keen and Zimmet). https://doi.org/10.1002/0470862092.d0310
Jacob S, Klimm HJ, Rett K, Helsberg K, Häring HU, Gödicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004 Jun;112(6):315-22. doi: 10.1055/s-2004-820915. PMID: 15216449.
Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994 Apr;43(4):455-61. doi: 10.1016/0026-0495(94)90076-0. PMID: 8159103.
Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004 Sep 21;141(6):413-20. doi: 10.7326/0003-4819-141-6-200409210-00006. PMID: 15381514.
Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012 Apr;59(4):893-8. doi: 10.1161/HYPERTENSIONAHA.111.189589. Epub 2012 Feb 21. PMID: 22353614; PMCID: PMC3402551.
Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996 Apr;14(4):489-94. Erratum in: J Hypertens 1996 Nov;14(11):1382. PMID: 8761899.
Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2227-36. doi: 10.1001/jama.292.18.2227. PMID: 15536109.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14. Erratum in: JAMA. 2003 Jul 9;290(2):197. PMID: 12748199.
Almeman AA, Beshir YA, Aldosary AH. Comparison of the Effects of Metoprolol and Bisoprolol on Lipid and Glucose Profiles in Cardiovascular Patients. Curr Drug Saf. 2019;14(1):27-30. doi: 10.2174/1574886313666181029101247. PMID: 30370856.
Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers. J Clin Hypertens (Greenwich). 2011 Jan;13(1):52-9. doi: 10.1111/j.1751-7176.2010.00386.x. Epub 2010 Nov 8. PMID: 21214722; PMCID: PMC8672984.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. PMID: 12853193.
Zhang W, Deng G, Hu J, Yan R, Hu J, Fan J. Effects of Carvedilol on Blood Pressure, Blood Sugar, and Blood Lipids in Elderly Patients with Refractory Hypertension. Comput Math Methods Med. 2022 Jul 27;2022:7889024. doi: 10.1155/2022/7889024. PMID: 35936366; PMCID: PMC9348927.
Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997 Jun 15;126(12):955-9. doi: 10.7326/0003-4819-126-12-199706150-00004. PMID: 9182472.
Metwally YG, Sedrak HK, Shaltout IF. Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure. Egypt Heart J. 2020 Sep 29;72(1):63. doi: 10.1186/s43044-020-00099-5. PMID: 32990863; PMCID: PMC7524985.
Wai et al.: Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovascular Diabetology 2012 11:14.
Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S96-9. doi: 10.1097/00005344-198511001-00018. PMID: 2439808.
Fritz, G.. (2001). Influence on Plasma-Insulin and Blood-Glucose by Treatment with Bisoprolol in Hipertensive Non-Diabetic Patients. Journal of Clinical and Basic Cardiology. 4.
Owada A, Suda S, Hata T, Miyake S. The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens. 2001 May;23(4):305-16. doi: 10.1081/ceh-100102669. PMID: 11349822.
Haneda T, Ido A, Fujikane T, Tanaka H, Tanazawa S, Morimoto H, Kato J, Kanaya K, Honda H, Sakai H, Akita N, Hirayama T, Onodera S, Kikuchi K. [Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension]. Nihon Ronen Igakkai Zasshi. 1998 Jan;35(1):33-8. Japanese. doi: 10.3143/geriatrics.35.33. PMID: 9564739.
Sowers J.. (2007). Long-term Effects of the Novel beta-blocker, Nebivolol, on Blood Glucose in Hypertensive Patients. Phoenix, AZ 2267-PO Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications
Van Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes:
a post-marketing surveillance study. Eur Rev Med Pharmacol Sci. 2010 Sep;14(9):749-58. PMID: 21061833.
Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens (Greenwich). 2013 Apr;15(4):270-8. doi: 10.1111/jch.12071. Epub 2013 Feb 1. PMID: 23551727; PMCID: PMC8033886.
Yuriy Sirenko, et.al. (2017)Effect of Beta - Blockers on Insulin Resistance in Patients with Hypertension and Metabolic Syndrome after 6 Months of Treatment. J Endocrinol Diab. 3(6): 1-11. DOI: http://dx.doi.org/10.15226/2374-6890/4/2/00175
Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Loguercio M, Mantegazza V, Karsten M, Sciomer S, Magrì D, Fiorentini C, Agostoni P. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure:
the CARNEBI trial. Int J Cardiol. 2013 Oct 3;168(3):2134-40. doi: 10.1016/j.ijcard.2013.01.277. Epub 2013 Mar 16. PMID: 23506636.
De Cree J, Van Nueten L, Geukens H, Verhaegen H. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res. 1992;12(4):159-63. PMID: 1363660.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53. doi: 10.2337/diacare.27.5.1047. PMID: 15111519.
Bussey CT, Babakr AA, Iremonger RR, et al. Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes. Physiol Rep. 2020;8:e14394. https://doi.org/10.14814/ phy2.14394
Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens. 1998 Oct;11(10):1258-65. doi: 10.1016/s0895-7061(98)00141-1. PMID: 9799045.
Taylor AA, Bakris GL. The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med. 2010 Jul;123(7 Suppl 1):S21-6. doi: 10.1016/j.amjmed.2010.04.015. PMID: 20609696.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Kamila Fularska, Michal Oleszko, Edward Wąsiewicz, Aleksandra Kuźniar, Dominik Szawica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 746
Number of citations: 0
